Join Pareen Mehta, MD as he discusses the advancement of RANO criteria, reviews RANO-HGG, iRANO and RANO-BM criteria, addresses the challenges of brain tumor assessment and the importance of neuroradiology input in clinical trial design. https://hubs.ly/Q02Jh4320 #braintumor #RANO #imagingCRO
Invicro
Biotechnology Research
Needham, MA 13,574 followers
A global CRO offering imaging biomarkers, core lab services, analytics & software solutions to pharma/biotech sponsors.
About us
Headquartered in Needham, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, and systemic and rare diseases. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®, as well as their pioneering IQ-Analytics Platform, which includes AmyloidIQ, TauIQ and DaTIQ.
- Website
-
http://www.invicro.com/
External link for Invicro
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Needham, MA
- Type
- Privately Held
- Founded
- 2008
- Specialties
- software development, advanced statistics, automated reporting, electronic record keeping, consulting, MRI, CT, SPECT, PET, Optical, Ultra Sound, iPACS, VivoQuant, clinical research, fMRI, BLI imaging, and CRO
Locations
-
Primary
Invicro, LLC.
119 Fourth Avenue
Needham, MA 02494, US
-
N/A
London, GB
-
60 Temple Street
New Haven, CT 06510, US
Employees at Invicro
Updates
-
Are standard imaging analysis solutions falling short? At Invicro, our Advanced Special Projects team tackles the most complex medical imaging challenges with custom AI/ML solutions. Whether it's automated data curation, volumetric segmentation, or multivariate prediction, we’ve got the know-how to advance your research. Curious to learn more? Let’s chat: https://hubs.ly/Q02JBKwx0
-
-
CNS imaging biomarkers are indispensable in gaining quantitative information on drug tissue distribution, drug target engagement and post-target pharmacodynamics effects. Join Dr. Ilan Rabiner as he provides insight on the value of imaging biomarkers for measuring pharmacodynamic effects of CNS drugs. https://bit.ly/4clIbDW #CNS #imagingCRO
-
-
Sitting on medical imaging data? Invicro’s Software with Image Analysis (SWIA) service offers advanced, tailored solutions for all imaging formats from 2D to 4D. Our capabilities span therapeutic areas, including oncology and CNS, as well as animal models. Enhance your research with precise, insightful analyses. Interested? Let’s chat: https://hubs.ly/Q02JBpW20 #medicalimaging #imagingCRO
-
-
Great collaboration! Learn more about the multimodal imaging study: https://lnkd.in/e_98HZ5X. #Neuroimaging #Invicro
Invicro is proud to have collaborated with the MRC Psychiatry Imaging Group and Sunovion on a very interesting multimodal imaging study combining 18F-DOPA and neuromelanin imaging in schizophrenia. See the URL below for the manuscript https://lnkd.in/e_98HZ5X Congratulations to Luke, Oliver and the rest of our co-authors
-
Neuroendocrine tumors (NET) require accurate diagnosis and staging for effective treatment and prognosis – limited disease can be treated with curative locoregional therapy, while patients with metastatic disease typically receive palliative systemic therapy. With 20-50% of patients presenting with metastases, sensitive and accessible imaging is crucial. In this prospective, Phase II study, researchers investigated a novel 18F-labeled somatostatin analog ([18F]FET-βAG-TOCA) for imaging NETs due to accessibility limitations of [68Ga]Ga-DOTA-peptides. The study demonstrated that [18F]FET-βAG-TOCA was not inferior to [68Ga]Ga-DOTA-peptide in visualizing NET and may be considered in routine clinical practice given the longer half-life and availability of the cyclotron-produced fluorine radioisotope. Learn more: https://hubs.ly/Q02KcQwm0
-
-
For over 20 years, Invicro leaders have made a profound impact in the field of bioluminescence imaging (BLI) research for pharma partners. Execution of these studies requires the skills of many scientific disciplines and the structure to enable the coordination of all facets of complex experiments. The speed & precision of our image analytics and reporting, coupled with supreme deep tissue tumor models has allowed Invicro to stay at the forefront of this powerful imaging modality. Learn more about our capabilities: https://bit.ly/3WspHeW #bioluminescenceimaging #imagingCRO #preclinicalimaging
-
-
As breast cancer treatments evolve toward personalized care, molecular imaging has become essential to optimize drug development and clinical decision-making. New imaging techniques, such as FES-PET, which uses a fluoroestradiol F-18 to visualize and measure the concentration of estrogen receptors in the body, may help overcome challenges in traditional approaches. Join Gisela Menezes Montgomery, MD, PhD as she discusses FES-PET and other recent advances in molecular breast cancer imaging. https://hubs.ly/Q02Hvgbm0 #breastcancer #CRO
-
-
What an incredible time at #AAIC2024! It was great connecting with so many brilliant minds on advancing Alzheimer’s research through imaging. Looking forward to continuing these important conversations. 🧠✨ Elif Sikoglu, Kyle LoPresto, Joseph Vacca, David Russell, Samuel Lockhart, Meghan Pajonas, MBA, Matt Tumasz
-
-
We're excited to kick off #TRPSummit! Stop by booth #13 to say hi to Sean Carlin, Jon Archbold, Ganesh Iyer, and Megan Neustadt. They are ready to demonstrate how Invicro's scientific and operational excellence can drive your preclinical and clinical RLT programs to success. ☢ #theranostics #radiopharmaceuticals #nuclearmedicine #molecularimaging
-